Skip to main
ARVN

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 9%

Bulls say

Arvinas is a clinical-stage biotechnology company with a strong pipeline of therapeutics aimed at degrading disease-causing proteins and treating a variety of serious diseases. With several promising programs in different stages of development and key partnerships in place, the company is well-positioned for success in the oncology and neuroscience markets. While there are risks inherent in the biotechnology industry, Arvinas's innovative approach and team of experts make it a solid investment for those looking for growth potential.

Bears say

Arvinas is experiencing a significant shift with the introduction of new CEO Randy Teel and a change in drug development philosophy, leading to a more focused and cohesive pipeline. The new strategy includes a clear focus on partnering earlier in the programs' lifecycles and a focus on both validated and novel targets, which could provide a differentiated profile. However, the company still faces challenges in narrowing its overall portfolio and successfully developing its product candidates.

Arvinas Inc (ARVN) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 9% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 11 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.